This announcement is a separate document:
海普瑞：深圳市海普瑞药业集团股份有限公司2022年跟踪评级报告
Hypertherm: Shenzhen Hypertherm Pharmaceutical Group Co., Ltd. 2022 Follow-up Rating Report
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.